Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | OXTR | P30559 | 2/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3818740 | 1.00 | CNR2 (0.48) | CNR2TSHRCNR1NPSR1POLB | |
| SCHEMBL3818296 | 1.00 | CNR2 (0.48) | CNR2TSHRCNR1NPSR1POLB | |
| SCHEMBL3816753 | 0.89 | GRM5 (0.45) | CNR2TSHRCNR1NPSR1POLB | |
| SCHEMBL2702366 | 0.87 | CNR2 (0.52) | CNR2TSHRCNR1NPSR1POLB | |
| SCHEMBL2703860 | 0.87 | CNR2 (0.52) | CNR2TSHRCNR1NPSR1POLB | |
| SCHEMBL2702362 | 0.87 | CNR2 (0.52) | CNR2TSHRCNR1NPSR1POLB | |
| SCHEMBL3814525 | 0.85 | CNR1 (0.51) | CNR2CNR1 | |
| SCHEMBL2703460 | 0.84 | CNR2 (0.50) | CNR2CNR1 | |
| SCHEMBL3924497 | 0.83 | CNR2 (0.44) | CNR2TSHRCNR1SCN9ASCN10A | |
| SCHEMBL3818568 | 0.79 | PTGS2 (0.41) | PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629346-B2 | Pyrazinecarboxamide derivatives as CB1 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-12-08 | — | — | US | disclosed |
| EP-2035394-B1 | 2-PYRAZINECARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-08-19 | — | — | EP | disclosed |
| EP-1934199-B1 | INDANE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2009-04-22 | — | — | EP | disclosed |
| US-20070293509-A1 | Pyrazinecarboxamide derivatives as CB1 antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293509-A1 | Pyrazinecarboxamide derivatives as CB1 antagonists | CNR1, CNR2, GPR119 | CNR2 2/4885TSHR 268/4885CNR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.